L-Myc Inhibitors

The class of L-Myc inhibitors encompasses a diverse array of compounds designed to specifically target and inhibit L-Myc, a member of the Myc family of transcription factors. CX-5461, for instance, inhibits RNA polymerase I, potentially affecting the synthesis of ribosomal RNA and indirectly modulating L-Myc expression. 10058-F4 disrupts the binding of Max to c-Myc, interfering with the formation of the L-Myc/Max heterodimer and its activity. Additionally, JQ1, a BET bromodomain inhibitor, can indirectly modulate L-Myc expression by disrupting chromatin interactions. KU-0060648 inhibits the mTOR signaling pathway, potentially influencing L-Myc expression and activity. THZ1, a selective covalent inhibitor of CDK7, may affect the transcriptional machinery, influencing L-Myc expression. YK-4-279 disrupts the binding of the EWS-FLI1 complex to RNA helicase A, potentially influencing L-Myc expression indirectly.

Moreover, Dinaciclib inhibits cyclin-dependent kinases, potentially affecting the cell cycle and influencing L-Myc expression and activity. AZD-8055 inhibits mTOR kinase, potentially influencing downstream signaling pathways and modulating L-Myc expression. CX-4945 inhibits casein kinase 2 (CK2), potentially modulating L-Myc expression through its downstream targets. OTX015 and UNC0638, both BET bromodomain inhibitors, can indirectly modulate L-Myc expression by disrupting chromatin interactions. In summary, the L-Myc inhibitors class presents a range of compounds that specifically target and inhibit L-Myc, influencing its expression and activity through various molecular mechanisms. Understanding the precise biochemical and cellular pathways influenced by these inhibitors provides valuable insights into the intricate regulatory network involving L-Myc in cellular processes.